Meeting
2016 ASCO Annual Meeting
A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503.
Authors
Federico Innocenti
The University of North Carolina at Chapel Hill, Chapel Hill, NC
Federico Innocenti , Kouros Owzar , Chen Jiang , Alexander Sibley , Flora Mulkey , Lisa A. Carey , Debu Tripathy , Bryan P. Schneider , William Thomas Barry , Eric P. Winer , Clifford A. Hudis , Howard L. McLeod , Maura N. Dickler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT00601900
Citation
J Clin Oncol 34, 2016 (suppl; abstr 538)
DOI
10.1200/JCO.2016.34.15_suppl.538
Abstract #
538
Poster Bd #
26
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).
First Author: Daniel Louis Hertz
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Genome-wide association study (GWAS) and novel prognostic markers in metastatic colorectal cancer (mCRC).
First Author: Yan Yang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO.
First Author: Yu Sunakawa
Poster
2020 ASCO Virtual Scientific Program
Genome Wide Association Study (GWAS) of cognitive impairment after blood or marrow transplantation (BMT) for hematologic malignancy.
First Author: Noha Sharafeldin